Wall Street Pummels Moderna Inc. (MRNA) After Recent Earnings Report – News Heater

Wall Street Pummels Moderna Inc. (MRNA) After Recent Earnings Report

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Moderna Inc. (NASDAQ:MRNA) went up by 1.79% from its latest closing price compared to the recent 1-year high of $189.26. The company’s stock price has collected 2.99% of gains in the last five trading sessions. The Wall Street Journal reported 15 hours ago that U.K. Covid-19 Variant’s Hold in U.S. Has Silver Lining: Vaccines Counter It

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Moderna Inc. (NASDAQ :MRNA) Right Now?

Opinions of the stock are interesting as 8 analysts out of 17 who provided ratings for Moderna Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 2 as “sell.”


5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored



The average price from analysts is $171.31, which is -$3.32 below the current price. MRNA currently public float of 356.19M and currently shorts hold a 3.33% ratio of that float. Today, the average trading volume of MRNA was 9.70M shares.

MRNA’s Market Performance

MRNA stocks went up by 2.99% for the week, with a monthly jump of 36.56% and a quarterly performance of 3.27%, while its annual performance rate touched 288.82%. The volatility ratio for the week stands at 5.33% while the volatility levels for the past 30 days are set at 5.75% for Moderna Inc.. The simple moving average for the period of the last 20 days is 14.36% for MRNA stocks with a simple moving average of 60.18% for the last 200 days.

Analysts’ Opinion of MRNA

Morgan Stanley, on the other hand, stated in their research note that they expect to see MRNA reach a price target of $150. The rating they have provided for MRNA stocks is “Equal-Weight” according to the report published on December 16th, 2020.

Jefferies gave a rating of “Hold” to MRNA, setting the target price at $150 in the report published on December 16th of the previous year.

MRNA Trading at 21.21% from the 50-Day Moving Average

After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.52% of loss for the given period.

Volatility was left at 5.75%, however, over the last 30 days, the volatility rate increased by 5.33%, as shares surge +34.91% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.45% upper at present.

During the last 5 trading sessions, MRNA rose by +2.99%, which changed the moving average for the period of 200-days by +122.91% in comparison to the 20-day moving average, which settled at $158.68. In addition, Moderna Inc. saw 71.17% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MRNA starting from Bancel Stephane, who sale 10,000 shares at the price of $182.49 back on Apr 29. After this action, Bancel Stephane now owns 7,434,880 shares of Moderna Inc., valued at $1,824,900 using the latest closing price.

HENDERSON LORI M., the General Counsel and Secretary of Moderna Inc., sale 6,600 shares at $182.49 during a trade that took place back on Apr 29, which means that HENDERSON LORI M. is holding 901 shares at $1,204,434 based on the most recent closing price.

Stock Fundamentals for MRNA

Current profitability levels for the company are sitting at:

  • -94.99 for the present operating margin
  • +95.12 for the gross margin

The net margin for Moderna Inc. stands at -92.99. The total capital return value is set at -37.14, while invested capital returns managed to touch -36.66. Equity return is now at value -30.20, with -17.00 for asset returns.

Based on Moderna Inc. (MRNA), the company’s capital structure generated 9.28 points at debt to equity in total, while total debt to capital is 8.49. Total debt to assets is 3.24, with long-term debt to equity ratio resting at 8.09. Finally, the long-term debt to capital ratio is 7.41.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

When we switch over and look at the enterprise to sales, we see a ratio of 44.15, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 1.13 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.